Living with lung cancer that has become resistant to standard treatments is incredibly hard. A recent study looked at three specific drug combinations compared to standard chemotherapy for patients in China with a specific type of non-small cell lung cancer.
The results showed that these newer combinations—including drugs like ivonescimab, sintilimab, and atezolizumab—actually improved the effectiveness of treatment compared to chemotherapy alone. However, there is a catch: these treatments also came with more side effects and were not considered cost-effective under current healthcare systems.
To make these better outcomes available to more people, the study suggests significant price cuts would be needed. For example, one drug combination would only become cost-effective if its main component's price dropped by at least 47.2%. While the medicine works better for the body, the high costs remain a major hurdle for the system.
